1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.2.1. Research Assumptions
1.2.2. Project Methodology
1.2.3. Forecast Methodology
1.2.4. Robust Quality Control
1.2.5. Key Considerations
1.2.5.1. Demographics
1.2.5.2. Economic Factors
1.2.5.3. Government Regulations
1.2.5.4. Supply Chain
1.2.5.5. COVID Impact / Related Factors
1.2.5.6. Market Access
1.2.5.7. Healthcare Policies
1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Discovery and Validation
3.3.3. Hit Generation
3.3.3.1. High-Throughput Screening
3.3.3.2. Fragment-based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA-Encoded Libraries Screening
3.3.4. Hit-to-Lead and Lead Generation
3.3.5. Lead Optimization
3.4. Challenges Associated with Small Molecule Discovery
3.5. Need for Outsourcing Drug Discovery Operations
3.6. Guidelines for Selecting a Contract Research Service Provider
3.7. Concluding Remarks
4. PHARMACEUTICAL CONTRACT RESEARCH SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Pharmaceutical Contract Research Service Providers: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Company Size and Scale of Operation
4.2.6. Analysis by Types of Services Offered
4.2.7. Analysis by Location of Headquarters and Types of Services Offered
4.2.8. Analysis by Hit Identification Strategy Used
4.2.9. Analysis by Type of Business Model
4.2.10. Analysis by Target Therapeutic Area
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Pharmaceutical Contract Research Service Providers in North America
5.2.1. Albany Molecular Research (AMRI)
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Service Portfolio
5.2.1.4. Recent Developments and Future Outlook
5.2.2. BioDuro
5.2.2.1. Company Overview
5.2.2.2. Service Portfolio
5.2.2.3. Recent Developments and Future Outlook
5.2.3. BOC Sciences
5.2.3.1. Company Overview
5.2.3.2. Service Portfolio
5.2.3.3. Recent Developments and Future Outlook
5.2.4. Catalent Pharma
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Service Portfolio
5.2.4.4. Recent Developments and Future Outlook
5.2.5. Charles River Laboratories
5.2.5.1. Company Overview
5.2.5.2. Financial Information
5.2.5.3. Service Portfolio
5.2.5.4. Recent Developments and Future Outlook
5.2.6. ChemDiv
5.2.6.1. Company Overview
5.2.6.2. Service Portfolio
5.2.6.3. Recent Developments and Future Outlook
5.2.7. Covance
5.2.7.1. Company Overview
5.2.7.2. Financial Information
5.2.7.3. Service Portfolio
5.2.7.4. Recent Developments and Future Outlook
5.2.8. Medpace
5.2.8.1. Company Overview
5.2.8.2. Financial Information
5.2.8.3. Service Portfolio
5.2.8.4. Recent Developments and Future Outlook
5.2.9. QPS
5.2.9.1. Company Overview
5.2.9.2. Service Portfolio
5.2.9.3. Recent Developments and Future Outlook
5.3. Pharmaceutical Contract Research Service Providers in Europe
5.3.1. Concept Life Sciences
5.3.1.1. Company Overview
5.3.1.2. Service Portfolio
5.3.1.3. Recent Developments and Future Outlook
5.3.2. Evotec
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Service Portfolio
5.3.2.4. Recent Developments and Future Outlook
5.4. Pharmaceutical Contract Research Service Providers in Asia-Pacific
5.4.1. ChemPartner
5.4.1.1. Company Overview
5.4.1.2. Financial Information
5.4.1.3. Service Portfolio
5.4.1.4. Recent Developments and Future Outlook
5.4.2. Pharmaron
5.4.2.1. Company Overview
5.4.2.2. Service Portfolio
5.4.2.3. Recent Developments and Future Outlook
5.4.3. Syngene
5.4.3.1. Company Overview
5.4.3.2. Financial Information
5.4.3.3. Service Portfolio
5.4.3.4. Recent Developments and Future Outlook
5.4.4. Torrent Pharma
5.4.4.1. Company Overview
5.4.4.2. Financial Information
5.4.4.3. Service Portfolio
5.4.4.4. Recent Developments and Future Outlook
5.4.5. WuXi AppTec
5.4.5.1. Company Overview
5.4.5.2. Financial Information
5.4.5.3. Service Portfolio
5.4.5.4. Recent Developments and Future Outlook
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers
6.4.1. Pharmaceutical Contract Research Service Providers based in North America
6.4.2. Pharmaceutical Contract Research Service Providers based in Europe
6.4.3. Pharmaceutical Contract Research Service Providers based in Asia- Pacific and Rest of the World
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Pharmaceutical Contract Research Service Providers: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Target Therapeutic Area
7.3.5. Analysis by Year of Partnership and Type of Partner
7.3.6. Analysis by Type of Partnership and Type of Partner
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Regional Analysis
7.3.8.1. Intercontinental and Intracontinental Agreements
8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. Merger and Acquisition Models
8.3. Pharmaceutical Contract Research Service Providers: Mergers and Acquisitions
8.3.1. Analysis by Year of Acquisition
8.3.2. Analysis by Geography
8.3.3. Intercontinental and Intracontinental Deals
8.4. Analysis by Key Value Drivers
8.4.1. Mergers and Acquisitions: Analysis by Key Value Drivers
8.5. Valuation Analysis: Acquisition Deal Multiples
8.5.1. Prominent Acquirers: Analysis by Number of Acquisitions
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Pharmaceutical Contract Research Service Providers Market, Till 2035
9.4. Global Pharmaceutical Contract Research Service Providers Market, Till 2035: Distribution by Scale of Operation
9.4.1. Global Pharmaceutical Contract Research Service Providers Market for Discovery Services, Till 2035
9.4.2. Global Pharmaceutical Contract Research Service Providers Market for Preclinical Services, Till 2035
9.4.3. Global Pharmaceutical Contract Research Service Providers Market for Clinical Services, Till 2035
9.5. Global Pharmaceutical Contract Research Service Providers Market, Till 2035: Distribution by Target Therapeutic Area
9.5.1. Global Pharmaceutical Contract Research Service Providers Market for Oncological Disorders, Till 2035
9.5.2. Global Pharmaceutical Contract Research Service Providers Market for Infectious Diseases, Till 2035
9.5.3. Global Pharmaceutical Contract Research Service Providers Market for Neurological Disorders, Till 2035
9.5.4. Global Pharmaceutical Contract Research Service Providers Market for Inflammatory Disorders, Till 2035
9.5.5. Global Pharmaceutical Contract Research Service Providers Market for Cardiovascular Disorders, Till 2035
9.5.6. Global Pharmaceutical Contract Research Service Providers Market for Dermatological Disorders, Till 2035
9.5.7. Global Pharmaceutical Contract Research Service Providers Market for Ophthalmological Diseases, Till 2035
9.5.8. Global Pharmaceutical Contract Research Service Providers Market for Respiratory Disorders, Till 2035
9.5.9. Global Pharmaceutical Contract Research Service Providers Market for Other Disorders, Till 2035
9.6. Global Pharmaceutical Contract Research Service Providers Market, Till 2035: Distribution by Region
9.6.1. Pharmaceutical Contract Research Service Providers Market in North America, Till 2035
9.6.2. Pharmaceutical Contract Research Service Providers Market in Europe, Till 2035
9.6.3. Pharmaceutical Contract Research Service Providers Market in Asia-Pacific, Till 2035
9.6.4. Pharmaceutical Contract Research Service Providers Market in Middle East, Till 2035
9.6.5. Pharmaceutical Contract Research Service Providers Market in Latin America, Till 2035
10. TOTAL COST OF OWNERSHIP IN PHARMACEUTICAL CONTRACT RESEARCH ORGANIZATION
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Output
11. CASE STUDY: BIOPHARMACEUTICAL CONTRACT RESEARCH SERVICES MARKET
11.1. Chapter Overview
11.2. Biopharmaceutical CROs: Overall Market Landscape
11.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
11.2.2. Analysis by Scale of Operation
11.3. Preclinical Biopharmaceutical CROs
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Location of Headquarters
11.3.4. Analysis by Type of Biologic
11.3.5. Analysis by Type of Services Offered
11.4. Clinical Biopharmaceutical CROs
11.4.1. Analysis by Year of Establishment
11.4.2. Analysis by Company Size
11.4.3. Analysis by Location of Headquarters
11.4.4. Analysis by Type of Biologics
11.4.5. Analysis by Type of Services Offered
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Company A
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Founder and Chief Executive Officer
LIST OF FIGURES
Figure 3.1 Drug Discovery and Development Pipeline
Figure 3.2 Drug Discovery Process
Figure 3.3 Guidelines for Selecting a Contract Research Service Provider
Figure 4.1 Pharmaceutical Contract Research Service Providers: Distribution by Year of Establishment
Figure 4.2 Pharmaceutical Contract Research Service Providers: Distribution by Company Size
Figure 4.3 Pharmaceutical Contract Research Service Providers: Distribution by Scale of Operation
Figure 4.4 Pharmaceutical Contract Research Service Providers: Distribution by Location of Headquarters
Figure 4.5 World Map Representation: Analysis by Geography
Figure 4.6 Pharmaceutical Contract Research Service Providers: Distribution by Company Size and Scale of Operation
Figure 4.7 Pharmaceutical Contract Research Service Providers: Distribution by Types of Services Offered
Figure 4.8 Pharmaceutical Contract Research Service Providers: Distribution by Location of Headquarters and Types of Services Offered
Figure 4.9 Pharmaceutical Contract Research Service Providers: Distribution by Hit Identification Strategy Used
Figure 4.10 Pharmaceutical Contract Research Service Providers: Distribution by Type of Business Model
Figure 4.11 Pharmaceutical Contract Research Service Providers: Distribution by Target Therapeutic Area
Figure 5.1 Catalent Pharma: Annual Revenues, Since 2016 (USD Billion)
Figure 5.2 Charles River Laboratories: Annual Revenues, Since 2016 (USD Billion)
Figure 5.3 Covance: Annual Revenues, Since 2016 (USD Billion)
Figure 5.4 Medpace: Annual Revenues, Since 2016 (USD Billion)
Figure 5.5 Evotec: Annual Revenues, Since 2016 (EUR Million)
Figure 5.6 Syngene: Annual Revenues, Since 2016 (INR Billion)
Figure 5.7 Torrent Pharma: Annual Revenues, Since 2016 (INR Million)
Figure 5.8 WuXi AppTec: Annual Revenues, Since 2017 (RMB Billion)
Figure 6.1 Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers based in North America
Figure 6.2 Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers based in Europe
Figure 6.3 Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers based in Asia Pacific and Rest of the World
Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2018
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 7.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 7.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.8 Most Active Players: Distribution by Number of Partnerships
Figure 7.9 Partnerships and Collaborations: Regional Distribution
Figure 7.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 8.1 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition Since 2018
Figure 8.2 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Figure 8.3 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
Figure 8.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 8.5 Mergers and Acquisitions: Region-wise Distribution
Figure 8.6 Mergers and Acquisitions: Country-wise Distribution
Figure 8.7 Mergers and Acquisitions: Ownership Change Matrix
Figure 8.8 Mergers and Acquisitions: Key Value Drivers
Figure 8.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 8.10 Mergers and Acquisitions: Deal Multiples Based on Revenue
Figure 8.11 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
Figure 9.1 Global Pharmaceutical Contract Research Services Market, Till 2035 (USD Billion)
Figure 9.2 Global Pharmaceutical Contract Research Services Market, Till 2035: Distribution by Scale of Operation (USD Billion)
Figure 9.3 Global Pharmaceutical Contract Research Services Market for Discovery Services, Till 2035 (USD Billion)
Figure 9.4 Global Pharmaceutical Contract Research Services Market for Preclinical Services, Till 2035 (USD Billion)
Figure 9.5 Global Pharmaceutical Contract Research Services Market for Clinical Stage Services, Till 2035 (USD Billion)
Figure 9.6 Global Pharmaceutical Contract Research Services Market, Till 2035: Distribution by Target Therapeutic Area (USD Billion)
Figure 9.7 Global Pharmaceutical Contract Research Services Market for Oncological Disorders, Till 2035 (USD Billion)
Figure 9.8 Global Pharmaceutical Contract Research Services Market for Infectious Diseases, Till 2035 (USD Billion)
Figure 9.9 Global Pharmaceutical Contract Research Services Market for Neurological Disorders, Till 2035 (USD Billion)
Figure 9.10 Global Pharmaceutical Contract Research Services Market for Inflammatory Disorders, Till 2035 (USD Billion)
Figure 9.11 Global Pharmaceutical Contract Research Services Market for Cardiovascular Disorders, Till 2035 (USD Billion)
Figure 9.12 Global Pharmaceutical Contract Research Services Market for Dermatological Disorders, Till 2035 (USD Billion)
Figure 9.13 Global Pharmaceutical Contract Research Services Market for Ophthalmological Diseases, Till 2035 (USD Billion)
Figure 9.14 Global Pharmaceutical Contract Research Services Market for Respiratory Disorders, Till 2035 (USD Billion)
Figure 9.15 Global Pharmaceutical Contract Research Services Market for Other Disorders, Till 2035 (USD Billion)
Figure 9.16 Global Pharmaceutical Contract Research Services Market, Till 2035: Distribution by Geography (USD Billion)
Figure 9.17 Global Pharmaceutical Contract Research Services Market in North America, Till 2035 (USD Billion)
Figure 9.18 Global Pharmaceutical Contract Research Services Market in Europe, Till 2035 (USD Billion)
Figure 9.19 Global Pharmaceutical Contract Research Services Market in Asia-Pacific, Till 2035 (USD Billion)
Figure 9.20 Global Pharmaceutical Contract Research Services Market in Middle East and North Africa, Till 2035 (USD Billion)
Figure 9.21 Global Pharmaceutical Contract Research Services Market in Latin America, Till 2035 (USD Billion)
Figure 10.1 Total Cost of Ownership in Pharmaceutical Contract Research Organization: Output
Figure 11.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 11.2 Biopharmaceutical CROs: Distribution by Scale of Operation
Figure 11.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Figure 11.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Figure 11.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Figure 11.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Figure 11.7 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Figure 11.8 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Figure 11.9 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 11.10 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Figure 11.11 Biopharmaceutical Clinical CROs: Distribution by Company Size
Figure 11.12 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Figure 11.13 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Figure 11.14 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Figure 11.15 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Figure 11.16 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 13.1 Concluding Remarks: Overall Market Landscape
Figure 13.2 Concluding Remarks: Partnerships and Collaborations
Figure 13.3 Concluding Remarks: Mergers and Acquisitions
Figure 13.4 Concluding Remarks: Market Forecast
Figure 13.5 Concluding Remarks: Total Cost of Ownership in Pharmaceutical Contract Research Organization
LIST OF TABLES
Table 4.1 Pharmaceutical Contract Research Service Providers: List of Industry Players
Table 4.2 Pharmaceutical Contract Research Service Providers: Information on Scale of Operation
Table 4.3 Pharmaceutical Contract Research Service Providers: Information on Types of Services Offered
Table 4.4 Pharmaceutical Contract Research Service Providers: Information on Hit Identification Strategy Used
Table 4.5 Pharmaceutical Contract Research Service Providers: Information on Type of Business Model
Table 4.6 Pharmaceutical Contract Research Service Providers: Information on Type of Business Model
Table 4.7 Pharmaceutical Contract Research Service Providers: Information on Target Therapeutic Area
Table 5.1 Pharmaceutical Contract Research Service Providers: List of Profiled Companies
Table 5.2 AMRI: Company Overview
Table 5.3 AMRI: Service Portfolio
Table 5.4 AMRI: Recent Developments and Future Outlook
Table 5.5 BioDuro: Company Overview
Table 5.6 BioDuro: Service Portfolio
Table 5.7 BioDuro: Recent Developments and Future Outlook
Table 5.8 BOC Sciences: Company Overview
Table 5.9 BOC Sciences: Service Portfolio
Table 5.10 BOC Sciences: Recent Developments and Future Outlook
Table 5.11 Catalent Pharma: Company Overview
Table 5.12 Catalent Pharma: Service Portfolio
Table 5.13 Catalent Pharma: Recent Developments and Future Outlook
Table 5.14 Charles River Laboratories: Company Overview
Table 5.15 Charles River Laboratories: Service Portfolio
Table 5.16 Charles River Laboratories: Recent Developments and Future Outlook
Table 5.17 ChemDiv: Company Overview
Table 5.18 ChemDiv: Service Portfolio
Table 5.19 ChemDiv: Recent Developments and Future Outlook
Table 5.20 Covance: Company Overview
Table 5.21 Covance: Service Portfolio
Table 5.22 Covance: Recent Developments and Future Outlook
Table 5.23 Medpace: Company Overview
Table 5.24 Medpace: Service Portfolio
Table 5.25 Medpace: Recent Developments and Future Outlook
Table 5.26 QPS: Company Overview
Table 5.27 QPS: Service Portfolio
Table 5.28 QPS: Recent Developments and Future Outlook
Table 5.29 Concept Life Sciences: Company Overview
Table 5.30 Concept Life Sciences: Service Portfolio
Table 5.31 Concept Life Sciences: Recent Developments and Future Outlook
Table 5.32 Evotec: Company Overview
Table 5.33 Evotec: Service Portfolio
Table 5.34 Evotec: Recent Developments and Future Outlook
Table 5.35 ChemPartner: Company Overview
Table 5.36 ChemPartner: Service Portfolio
Table 5.37 ChemPartner: Recent Developments and Future Outlook
Table 5.38 Pharmaron: Company Overview
Table 5.39 Pharmaron: Service Portfolio
Table 5.40 Pharmaron: Recent Developments and Future Outlook
Table 5.41 Syngene: Company Overview
Table 5.42 Syngene: Service Portfolio
Table 5.43 Syngene: Recent Developments and Future Outlook
Table 5.44 Torrent Pharma: Company Overview
Table 5.45 Torrent Pharma: Service Portfolio
Table 5.46 Torrent Pharma: Recent Developments and Future Outlook
Table 5.47 WuXi AppTec: Company Overview
Table 5.48 WuXi AppTec: Service Portfolio
Table 5.49 WuXi AppTec: Recent Developments and Future Outlook
Table 7.1 Pharmaceutical Contract Research Service Providers: List of Partnerships and Collaborations
Table 8.1 Mergers and Acquisitions: List of Mergers / Acquisitions, Since 2018
Table 8.2 Mergers and Acquisitions: Information on Key Value Drivers, Since 2018
Table 8.3 Mergers and Acquisitions: Deal Multiples, Since 2018
Table 11.2 Biopharmaceutical Preclinical CROs: Information on Types of Services Offered
Table 11.3 Biopharmaceutical Clinical CROs: Information on Types of Services Offered
Table 12.1 ChemoGenics Biopharma: Key Highlights
Table 14.1 Pharmaceutical Contract Research Service Providers: Distribution by Year of Establishment
Table 14.2 Pharmaceutical Contract Research Service Providers: Distribution by Scale of Operation
Table 14.3 Pharmaceutical Contract Research Service Providers: Distribution by Company Size
Table 14.4 Pharmaceutical Contract Research Service Providers: Distribution by Location of Headquarters
Table 14.5 World Map Representation: Analysis by Geography
Table 14.6 Pharmaceutical Contract Research Service Providers: Distribution by Company Size and Scale of Operation
Table 14.7 Pharmaceutical Contract Research Service Providers: Distribution by Types of Services Offered
Table 14.9 Pharmaceutical Contract Research Service Providers: Distribution by Hit Identification Strategy Used
Table 14.10 Pharmaceutical Contract Research Service Providers: Distribution by Type of Business Model
Table 14.11 Pharmaceutical Contract Research Service Providers: Distribution by Target Therapeutic Area
Table 14.12 Catalent Pharma: Annual Revenues, Since 2016 (USD Billion)
Table 14.13 Charles River Laboratories: Annual Revenues, Since 2016 (USD Billion)
Table 14.14 Covance: Annual Revenues, Since 2016 (USD Billion)
Table 14.15 Medpace: Annual Revenues, Since 2016 (USD Billion)
Table 14.16 Evotec: Annual Revenues, Since 2016 (EUR Million)
Table 14.17 Syngene: Annual Revenues, Since 2016 (INR Billion)
Table 14.18 Torrent Pharma: Annual Revenues, Since 2016 (INR Million)
Table 14.19 WuXi AppTec: Annual Revenues, Since 2017 (RMB Billion)
Table 14.20 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2018
Table 14.21 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.22 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.23 Partnerships and Collaborations: Distribution by Scale of Operation
Table 14.24 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 14.25 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.26 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.27 Most Active Players: Distribution by Number of Partnerships
Table 14.28 Partnerships and Collaborations: Regional Distribution
Table 14.29 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 14.30 Mergers and Acquisitions: List of Mergers / Acquisitions, Since 2016
Table 14.31 Mergers and Acquisitions: Information on Key Value Drivers, Since 2016
Table 14.32 Mergers and Acquisitions: Deal Multiples, Since 2016
Table 14.33 Global Pharmaceutical Contract Research Services Market, Till 2035 (USD Billion)
Table 14.34 Global Pharmaceutical Contract Research Services Market, Till 2035: Distribution by Scale of Operation (USD Billion)
Table 14.35 Global Pharmaceutical Contract Research Services Market for Discovery Services, Till 2035 (USD Billion)
Table 14.36 Global Pharmaceutical Contract Research Services Market for Preclinical Services, Till 2035 (USD Billion)
Table 14.37 Global Pharmaceutical Contract Research Services Market for Clinical Stage Services, Till 2035 (USD Billion)
Table 14.38 Global Pharmaceutical Contract Research Services Market, Till 2035: Distribution by Target Therapeutic Area (USD Billion)
Table 14.39 Global Pharmaceutical Contract Research Services Market for Oncological Disorders, Till 2035 (USD Billion)
Table 14.40 Global Pharmaceutical Contract Research Services Market for Infectious Diseases, Till 2035 (USD Billion)
Table 14.41 Global Pharmaceutical Contract Research Services Market for Neurological Disorders, Till 2035 (USD Billion)
Table 14.42 Global Pharmaceutical Contract Research Services Market for Inflammatory Disorders, Till 2035 (USD Billion)
Table 14.43 Global Pharmaceutical Contract Research Services Market for Cardiovascular Disorders, Till 2035 (USD Billion)
Table 14.44 Global Pharmaceutical Contract Research Services Market for Dermatological Disorders, Till 2035 (USD Billion)
Table 14.45 Global Pharmaceutical Contract Research Services Market for Ophthalmological Disorders, Till 2035 (USD Billion)
Table 14.46 Global Pharmaceutical Contract Research Services Market for Respiratory Disorders, Till 2035 (USD Billion)
Table 14.47 Global Pharmaceutical Contract Research Services Market for Other Disorders, Till 2035 (USD Billion)
Table 14.48 Global Pharmaceutical Contract Research Services Market, Till 2035: Distribution by Geography (USD Billion)
Table 14.49 Global Pharmaceutical Contract Research Services Market in North America, Till 2035 (USD Billion)
Table 14.50 Global Pharmaceutical Contract Research Services Market in Europe, Till 2035 (USD Billion)
Table 14.51 Global Pharmaceutical Contract Research Services Market in Asia-Pacific, Till 2035 (USD Billion)
Table 14.52 Global Pharmaceutical Contract Research Services Market in Middle East and North Africa, Till 2035 (USD Billion)
Table 14.53 Global Pharmaceutical Contract Research Services Market in Latin America, Till 2035 (USD Billion)
Table 14.54 Total Cost of Ownership in Pharmaceutical Contract Research Organization: Output
Table 14.55 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 14.56 Biopharmaceutical CROs: Distribution by Scale of Operation
Table 14.57 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Table 14.58 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Table 14.59 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Table 14.60 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Table 14.61 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Table 14.62 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Table 14.63 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
Table 14.64 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Table 14.65 Biopharmaceutical Clinical CROs: Distribution by Company Size
Table 14.66 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Table 14.67 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Table 14.68 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Table 14.69 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Table 14.70 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
